Idiopathic anaphylaxis (IA) is a severe allergic reaction without identifiable external triggers, presenting significant challenges in diagnosis and management. However, growing evidence suggests that many cases classified as idiopathic may actually be driven by cofactors such as exercise, hormonal fluctuations, medications, or hidden allergens. This mini-review explores the evolving understanding of IA, highlighting the role of these cofactors in triggering or amplifying anaphylactic reactions. It emphasizes how advances in diagnostic tools, including component-resolved diagnostics, are helping to identify previously undetected allergens, leading to more accurate diagnoses and reducing the prevalence of true idiopathic cases. As our knowledge of anaphylaxis and its underlying mechanisms deepens, the need for comprehensive evaluations that account for cofactor involvement becomes increasingly clear. Continued research in this area is essential to improve patient outcomes and better manage this complex condition.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527779 | PMC |
| http://dx.doi.org/10.3389/falgy.2024.1468945 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions.
Allergol Select
November 2024
Institute of Allergology, Charité Universitätsmedizin Berlin und Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin.
Article Synopsis
- Targeted therapies using biologics for atopic diseases, urticaria, and angioedema are advancing quickly, with several new antibodies developed, tested, and approved for clinical use, like omalizumab and dupilumab.
- There is ongoing research into combining different biologics for enhanced treatment efficacy, expanding their applications to conditions like food allergies and eosinophilic esophagitis.
- There are emerging concerns about unexpected side effects and hypersensitivity reactions associated with these therapies, raising important questions about their safety and mechanisms, particularly in specific patient groups like children.
Omalizumab for mast cell disorders.
J Allergy Clin Immunol
November 2024
Division of Allergy and Immunology, Department of Medicine, University of Michigan, Ann Arbor. Electronic address:
Asthma and respiratory comorbidities.
J Allergy Clin Immunol
November 2024
Department of Internal Medicine, Division of Allergy and Immunology, Morsani College of Medicine, University of South Florida, Tampa, and the James A. Haley VA Hospital, Tampa, Fla.
Asthma is a common respiratory condition with various phenotypes, nonspecific symptoms, and variable clinical course. The occurrence of other respiratory conditions with asthma, or respiratory comorbidities (RCs), is not unusual. A literature search of PubMed was performed for asthma and a variety of respiratory comorbidities for the years 2019 to 2024.
View Article and Find Full Text PDFA case with recurrent idiopathic anaphylaxis episodes starting soon after COVID-19 mRNA vaccination.
Allergol Immunopathol (Madr)
November 2024
Department of Internal Medicine, Division of Allergy and Clinical Immunology, Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Introduction: A patient was presented with a history of idiopathic recurrent anaphylaxis after administration of Pfizer BioNTech mRNA vaccine, and the attacks were controlled with omalizumab. To our knowledge, this is the first reported case of recurrent idiopathic anaphylaxis (IA) after administration of Pfizer BioNTech mRNA vaccine.
Case Presentation: A 52-year-old man with recurrent episodes of IA after COVID-19 vaccination presented to our adult Allergy and Immunology Clinic.
Demographics, Types of Patient-Reported Allergic Diseases, and Anaphylaxis in Mastocytosis: A Single-Center US Experience.
J Allergy Clin Immunol Pract
November 2024
Department of Internal Medicine, Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich. Electronic address:
Background: Patients with mastocytosis are at increased risk of anaphylaxis. Idiopathic anaphylaxis and venom-induced allergy are commonly reported in mastocytosis; however, the incidence of other allergies has been less well studied.
Objective: To characterize the true prevalence of allergic disease including food, venom, contrast, and drug allergy compared with the number of patients who simply avoid potential triggers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!